IMS reports 3% rise in Q4 sales, 6% decline for 2009
The healthcare data giant said sales increased to $599.2m for the three months ended 31 December. Operating income was down by 16% to $106.3m while net profit fell 27% to $71.5m
IMS said income was negatively affected by restructuring charges, costs associated with its planned takeover by investment groups TPG Capital and the CCP Investment Board, and other expense items totalling $27.7m. Adjusted figures show net profit up almost 5% to $95.1m.
Last summer, the firm announced a year-long plan to cut 850 jobs globally alongside other cost-reduction measures off the back of revenue falls in Q1 and Q2. Third-quarter sales also declined, but less severly than in previous quarters.
IMS chief executive David Carlucci (pictured) said: “IMS finished the year with an improved fourth-quarter performance, reflecting solid sequential revenue growth and better demand in the second half of the year. Our cost reduction plans remain on track.”
Full-year revenue was down 6% to $2.19bn, while net income fell 17% to $258.5m.
IMS shareholders voted earlier this week in favour of TPG and CCP’s $5bn takeover of the company. Save for a few remaining conditions, the deal is expected to complete before the end of the first quarter.

We hope you enjoyed this article.
Research Live is published by MRS.
The Market Research Society (MRS) exists to promote and protect the research sector, showcasing how research delivers impact for businesses and government.
Members of MRS enjoy many benefits including tailoured policy guidance, discounts on training and conferences, and access to member-only content.
For example, there's an archive of winning case studies from over a decade of MRS Awards.
Find out more about the benefits of joining MRS here.
0 Comments